Ziliomics receives seed financing to develop a bioinformatics software platform

by • July 4, 2018 • Feature Slider, Feature-Home, Featured-Slides-HomeComments Off on Ziliomics receives seed financing to develop a bioinformatics software platform267

Zilomics Inc. a start-up by FACIT focused on developing and commercializing a bioinformatics software platform receives seed financing from the Prospects Oncology Fund. Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer. Together with FACIT’s interim executive management model, the capital advances the development of Heliotrope, Ziliomics’ lead software product, and positions the company for corporate partnerships and additional financing. 

“With this financing and our continued partnership with the Adaptive Oncology team at OICR, Heliotrope is moving closer toward becoming a commercial software product. The modular architecture enables implementation in cloud-based infrastructure by any clinical genomics lab, allowing widespread adoption,” says Connie Chen, president and director of Ziliomics. “FACIT’s start-up and financing models ensure Ziliomics has the optimal path for corporate growth whether through additional investment or strategic partnerships.”

The Heliotrope platform was initially developed by a globally recognized team of informatics and genomics experts at the Ontario Institute for Cancer Research (OICR), an international nexus for cancer genomics research and FACIT’s strategic partner. With the growing impact of artificial intelligence on healthcare, FACIT established Ziliomics to manage the development and commercialization of Heliotrope and other bioinformatics software tools at the leading interface of healthcare and computing. Heliotrope incorporates machine-led, human verification processes to facilitate the interpretation of large volumes of genomic sequencing data in both an automated and authenticated manner.

“Since the human genome project, OICR has been a central player in the genomics revolution of healthcare and a well-respected leader in cancer research,” says David O’Neill, president of FACIT. “Our investment leverages years of evolving expertise that culminated in this exciting genomics intelligence tool called Heliotrope. Ziliomics aligns with FACIT’s strategy to accelerate early-stage oncology innovations in Ontario.”

Comments are closed.